Akademik Veri Yönetim Sistemi
CELL BIOCHEMISTRY AND FUNCTION, sa.4, 2024 (SCI-Expanded)
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder characterized by monoclonal B cell proliferation. Studies carried out in recent years suggest that extracellular vesicles (EVs) may be a potential biomarker in cancer. Tyro3-Axl-Mertk (TAM) Receptor Tyrosine Kinases (RTKs) and Phosphatidylserine (PS) have crucial roles in macrophage-mediated immune response under normal conditions. In the tumor microenvironment, these molecules contribute to immunosuppressive signals and prevent the formation of local and systemic antitumor immune responses. Based on this, we aimed to evaluate the amount of PS and TAM RTK in plasma and on the surface of EVs in CLL patients and healthy volunteers in this study. In this study, 25 CLL (11 F/14 M) patients in the Rai (O-I) stage, newly diagnosed or followed up without treatment, and 15 healthy volunteers (11 F/4 M) as a control group were included. For all samples, PS and TAM RTK levels were examined first in the plasma and then in the EVs obtained from the plasma. We detected a significant decrease in plasma PS, and TAM RTK levels in CLL patients compared to the control. Besides, we determined a significant increase in TAM RTK levels on the EV surface in CLL, except for PS. In conclusion, these receptor levels measured by ELISA in plasma may not be effective for the preliminary detection of CLL. However, especially TAM RTKs on the surface of EVs may be good biomarkers and potential targets for CLL therapies. In our study, we aimed to compare Phosphatidylserine and Tyro3-Axl-Mertk (TAM) Receptor Tyrosine Kinases (RTKs) levels on extracellular vesicles (EVs) surfaces in chronic lymphocytic leukemia (CLL) patients and healthy volunteers. Our results showed a significant increase in TAM RTK levels on the surface of EV of patients compared to those of healthy volunteers. We believe the data of this study will shed light on future studies. Larger studies involving advanced CLL patients may provide more information on this topic. Thus, the development of new treatments targeting such molecules can be achieved.